[1]张 珑,李月峰,吴 涛,等.前列腺癌患者血清miR-138-5p，miR-212-5p 水平表达及与临床预后价值[J].现代检验医学杂志,2024,39(05):30-34.[doi:10.3969/j.issn.1671-7414.2024.05.006]
　ZHANG Long,LI Yuefeng,WU Tao,et al.Expression of Serum miR-138-5p and miR-212-5p Levels and Clinical Prognosis Value in Prostate Cancer[J].Journal of Modern Laboratory Medicine,2024,39(05):30-34.[doi:10.3969/j.issn.1671-7414.2024.05.006]
点击复制

前列腺癌患者血清miR-138-5p，miR-212-5p 水平表达及与临床预后价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年05期
页码:
30-34
栏目:
论著
出版日期:
2024-09-15

文章信息/Info

Title:
Expression of Serum miR-138-5p and miR-212-5p Levels and Clinical Prognosis Value in Prostate Cancer
文章编号:
1671-7414（2024）05-030-05
作者:
张 珑; 李月峰; 吴 涛; 朱琳杰; 王海东
（邯郸市第一医院泌尿二科，河北邯郸 056002）
Author(s):
ZHANG Long;  LI Yuefeng;  WU Tao;  ZHU Linjie;  WANG Haidong
（the Second Department of Urology, the First Hospital of Handan, Hebei Handan 056002, China）
关键词:
前列腺癌; 微小RNA-138-5p; 微小RNA-212-5p; 预后价值
分类号:
R737.25；R730.43
DOI:
10.3969/j.issn.1671-7414.2024.05.006
文献标志码:
A
摘要:
目的 探究前列腺癌（prostate cancer）患者血清微小RNA（microRNA，miR）-138-5p，miR-212-5p 水平表达及与临床预后价值。方法 选择2020 年7 月～ 2021 年6 月邯郸市第一医院收治的95 例前列腺癌患者，根据术后两年的随访记录分为预后不良组（复发或死亡，n=52）和预后良好组（未复发或好转，n=43），另选同期48 例健康体检志愿者为健康对照组。实时荧光定量聚合酶链式反应（quantitative real-time fluorescence-PCR，qRT-PCR）检测血清miR-138-5p 和miR-212-5p 相对表达水平，收集并分析患者临床资料，多因素COX 回归分析影响前列腺癌患者预后的因素；绘制受试者工作特征（receiver operating characteristic，ROC）曲线分析血清miR-138-5p 和miR-212-5p 对前列腺癌患者预后情况的预测价值；Pearson 分析miR-138-5p，miR-212-5p 与Gleason 评分的相关性。结果 与健康对照组相比较，预后良好组、预后不良组患者血清miR-138-5p（0.88±0.10，0.83±0.09 vs 1.01±0.10），miR-212-5p（0.75±0.09，0.71±0.08vs 1.02±0.11）水平显著降低，差异具有统计学意义（t=14.021，22.275；9.825，18.063，均P ＜ 0.05）；前列腺癌患者预后情况与TNM 分期、骨转移、组织分化程度、术前PSA 水平以及Gleason 评分有关（χ2=4.417 ～ 7.187，t=14.235，均P ＜ 0.05）；血清miR-138-5p[HR（95%CI）：0.871（0.785 ～ 0.966）]，miR-212-5p[HR（95%CI）：0.822（0.725 ～ 0.932）]为预后不良的保护因素（均P＜ 0.05）。Gleason 评分[HR（95%CI）：1.253（1.026 ～ 1.530）]，TNM分期[HR（95%CI）：1.224（1.024 ～ 1.463）]，骨转移[HR（95%CI）：1.398（1.036 ～ 1.887）]，组织分化程度[HR（95%CI）：1.520（1.146 ～ 2.016）]和PSA 水平[HR（95%CI）：1.426（1.094 ～ 1.858）] 为预后不良的危险因素（均P ＜ 0.05）；血清miR-138-5p，miR-212-5p 预测的曲线下面积(95% 置信区间)[AUC(95%CI)] 分别为0.883（95%CI：0.801 ～ 0.940），0.863（95%CI：0.777 ～ 0.925）；血清miR-138-5p，miR-212-5p 与Gleason 评分均呈负相关（r=-0.610，-0.420，均P ＜ 0.05）。结论前列腺癌预后不良患者血清miR-138-5p 和miR-212-5p 水平显著升高，且对前列腺癌患者预后具有一定辅助预测价值。
Abstract:
Objective To investigate the clinical prognosis value of serum microRNA (miR) -138-5p and miR-212-5p levels in prostate cancer. Methods A total of 95 cases of prostate cancer patients admitted to the First Hospital of Handan from July 2020 to June 2021 were collected. Based on follow-up records for two years after surgery, these patients were separated into a poor prognosis group (n=52) and a good prognosis group (n=43), and 48 healthy volunteers who underwent a physical examination at the hospital were collected as the healthy control group. In addition, quantitative real-time fluorescence-PCR (qRT-PCR) was applied to detect the relative expression levels of miR-138-5p and miR-212-5p in the serum of study subjects, and the clinical data of the patients were collected and analyzed. Multivariate COX regression was applied to analyze factors that affected the prognosis of prostate cancer patients. The predictive value of serum miR-138-5p and miR-212-5p for the prognosis of prostate patients was tested, and receiver operating characteristic (ROC) curves were plotted. Pearson method was applied to analyze the correlation between the expression of serum miR-138-5p and miR-212-5p and the Gleason score. Results Compared to the healthy control group, the serum levels of miR-138-5p (0.88±0.10, 0.83±0.09 vs 1.01±0.10), and miR-212-5p (0.75±0.09, 0.71±0.08 vs 1.02±0.11) were lower in the good prostate cancer prognosis group and poor prostate cancer prognosis group， and the differences were significant (t=14.021，22.275；9.825，18.063， all P<0.05). The prognosis of prostate cancer patients was related to TNM staging, bone metastasis, tissue differentiation degree, preoperative PSA level, and Gleason score (χ2=4.417 ～ 7.187, t=14.235, all P<0.05). Serum miR-138-5p [HR(95%CI): 0.871(0.785 ～ 0.966)], and miR-212-5p [HR(95%CI): 0.822(0.725 ～ 0.932)] were protective factors for poor prognosis (all P<0.05). While Gleason score [HR(95%CI): 1.253(1.026 ～ 1.530)], TNM stage [HR(95%CI): 1.224(1.024 ～ 1.463)], bone metastasis [HR(95%CI): 1.398(1.036 ～ 1.887)], tissue differentiation degree [HR(95%CI): 1.520(1.146 ～ 2.016)] and PSA level [HR(95%CI): 1.426(1.094 ～ 1.858)] were all risk factors for poor prognosis (all P<0.05). The AUC (95%CI) of serum miR-138-5p and miR-212-5p were 0.883 (95%CI: 0.801~0.940) and 0.863 (95%CI: 0.777~0.925), respectively. Serum miR-138-5p and miR-212-5p were negatively correlated with the Gleason score (r=-0.610，-0.420, all P<0.05). Conclusion Serum miR-138-5p and miR-212-5p levels are elevated in patients with poor prostate cancer prognosis and may have a certain auxiliary predictive value for prostate cancer patient prognosis.

参考文献/References:

[1] DESAI K, MCMANUS J M, SHARIFI N. Hormonal therapy for prostate cancer[J]. Endocrine Reviews, 2021, 42(3): 354-373.
[2] 阴铭迪, 李林．前列腺癌实验室诊断的最新进展[J].现代检验医学杂志, 2022, 37(5): 194-198． YIN Mingdi, LI Lin. Recent advances in laboratory diagnosis of prostate cancer[J]. Journal of Modern Laboratory Medicine, 2022, 37(5): 194-198.
[3] WASIM S, LEE S Y, KIM J. Complexities of prostate cancer[J]. International Journal of Molecular Sciences, 2022, 23(22): 14257.
[4] KABEKKODU S P, SHUKLA V, VARGHESE V K, et al. Clustered miRNAs and their role in biological functions and diseases[J]. Biological Reviews of the Cambridge Philosophical Society, 2018, 93(4): 1955- 1986.
[5] SENGUPTA D, DEB M, KAR S, et al. Dissecting miRNA facilitated physiology and function in human breast cancer for therapeutic intervention[J]. Seminars in Cancer Biology, 2021, 72: 46-64.
[6] HSIEH T H, LIU Yunru, CHANG Tingyu, et al. Global DNA methylation analysis reveals miR-214- 3p contributes to cisplatin resistance in pediatric intracranial nongerminomatous malignant germ cell tumors[J]. Neuro-oncology, 2018, 20(4): 519-530.
[7] WANG Xinyi, ZHANG Haiyang, BAI Ming, et al. Exosomes serve as nanoparticles to deliver anti-miR-214 to reverse chemoresistance to cisplatin in gastric cancer[J]. Molecular Therapy, 2018, 26(3): 774-783.
[8] PAN Xufeng, CHEN Yong, SHEN Yuzhou, et al. Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7[J]. Cell Death & Disease, 2019, 10(6): 429.
[9] DU Feng, LI Zhijun, ZHANG Guohua, et al. SIRT2, a direct target of miR-212-5p, suppresses the proliferation and metastasis of colorectal cancer cells[J]. Journal of Cellular and Molecular Medicine, 2020, 24(17): 9985- 9998.
[10] DENG J H, ZHENG G Y, LI H Z, et al. MiR-212- 5p inhibits the malignant behavior of clear cell renal cell carcinoma cells by targeting TBX15[J]. European Review for Medical and Pharmacological Sciences, 2019, 23(24): 10699-10707.
[11] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2019[J]. CA:A Cancer Journal for Clinicians, 2019, 69(1): 7-34.
[12] 冷俊, 周晔, 施利琴, 等．环靶明对前列腺癌PC3细胞株生长的影响及其作用机制研究[J]．现代检验医学杂志, 2019, 34(2): 100-103． LENG Jun, ZHOU Ye, SHI Liqin, et al. Study on the effect and mechanism of Cyclopamine on proliferation of PC3 prostate cancer cell line[J]. Journal of Modern Laboratory Medicine, 2019, 34(2): 100-103.
[13] ZHANG Ning, HUANG Da, RUAN Xiaohao, et al. CRISPR screening reveals gleason score and castration resistance related oncodriver ring finger protein 19 A (RNF19A) in prostate cancer[J]. Drug Resistance Updates, 2023, 67: 100912.
[14] QIAN Mingyu, WANG Shaobo, GUO Xiaofan, et al. Hypoxic glioma-derived exosomes deliver microRNA-1246 to induce M2 macrophage polarization by targeting TERF2IP via the STAT3 and NF-κB pathways[J]. Oncogene, 2020, 39(2): 428-442.
[15] WU Jiaen, HAN Xuejia, YANG Xiancong, et al. MiR-138- 5p suppresses the progression of lung cancer by targeting SNIP1[J]. Thoracic Cancer, 2023, 14(6): 612-623.
[16] XUN Jing, DU Lingfang, GAO Ruifang, et al. Cancerderived exosomal miR-138-5p modulates polarization of tumor-associated macrophages through inhibition of KDM6B[J]. Theranostics, 2021, 11(14): 6847-6859.
[17] ZHANG Dapeng, LIU Xiaodong, ZHANG Qingwei, et al. MiR-138-5p inhibits the malignant progression of prostate cancer by targeting FOXC1[J]. Cancer Cell International, 2020, 20: 297.
[18] JIA Qin, CHANG Jing, HONG Qing, et al. MiR-212- 5p exerts a protective effect in chronic obstructive pulmonary disease[J]. Discovery Medicine, 2018, 26(144): 173-183.
[19] ZHENG Tianlei, LI Yan, ZHANG Xiaozai, et al. Exosomes derived from miR-212-5p overexpressed human synovial mesenchymal stem cells suppress chondrocyte degeneration and inflammation by targeting ELF3[J]. Frontiers in Bioengineering and Biotechnology, 2022, 10: 816209.
[20] JIA Pengbo, WEI Guangbing, ZHOU Cancan, et al. Upregulation of miR-212 inhibits migration and tumorigenicity and inactivates Wnt/β-Catenin signaling in human hepatocellular carcinoma[J]. Technology in Cancer Research & Treatment, 2018, 17: 1533034618765221.
[21] HAN Ruiyang, LI Yazhou, CAO Wei. The overexpression of miRNA-212-5p inhibited the malignant proliferation of liver cancer cells HepG2 and the tumor formation in nude mice with transplanted tumor through down-regulating SOCS5[J]. Translational Cancer Research, 2020, 9(6): 3986-3997.
[22] HU Bo, JIN Xunbo, WANG Jianbo. MicroRNA-212 targets mitogen-activated protein kinase 1 to inhibit proliferation and invasion of prostate cancer cells[J]. Oncology Research, 2018, 26(7): 1093-1102.
[23] WANG Xiaochuan, ZHANG Yu, JI Zhengguo, et al. Old men with prostate cancer have higher risk of Gleason score upgrading and pathological upstaging after initial diagnosis: a systematic review and metaanalysis[ J]. World Journal of Surgical Oncology, 2021, 19(1): 18.

相似文献/References:

[1]廖洪利,米叶赛尔·阿不都拉.粘着斑激酶在前列腺癌中表达的研究[J].现代检验医学杂志,2016,31(05):132.[doi:10.3969/j.issn.1671-7414.2016.05.038]
　LIAO Hong-li,MIYESAIER·Abdula.Research on Expression of FAK in Prostate Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(05):132.[doi:10.3969/j.issn.1671-7414.2016.05.038]
[2]范维肖,刁艳君,马越云,等.超速离心法与QIAGEN膜亲和柱法提取前列腺癌细胞培养上清外泌体的方法学比较[J].现代检验医学杂志,2019,34(03):6.[doi:10.3969/j.issn.1671-7414.2019.03.002]
　FAN Wei-xiao,DIAO Yan-jun,MA Yue-yun,et al.Comparison of Ultracentrifugation and Membrane Based-Affinity ColumnMethods in Exosome Isolation from Supernatants of Prostate Cancer Cells[J].Journal of Modern Laboratory Medicine,2019,34(05):6.[doi:10.3969/j.issn.1671-7414.2019.03.002]
[3]潘良明,沈菲菲,马晓英,等.血清前列腺健康指数对 tPSA灰区前列腺癌患者的诊断价值探讨[J].现代检验医学杂志,2021,36(01):72.[doi:10.3969/j.issn.1671-7414.2021.01.019]
　PAN Liang-ming,SHEN Fei-fei,MA Xiao-ying,et al.Diagnostic Value of Serum Prostate Health Index in Prostate Cancer Patients with PSA Gray Area[J].Journal of Modern Laboratory Medicine,2021,36(05):72.[doi:10.3969/j.issn.1671-7414.2021.01.019]
[4]何　跃,梁　晶,文礼红,等.前列腺癌患者血清IL-17和IL-35水平表达与临床病理特征以及预后的关系研究[J].现代检验医学杂志,2021,36(04):96.[doi:10.3969/j.issn.1671-7414.2021.04.020]
　HE Yue,LIANG Jing,WEN Li-hong,et al.Study on the Relationship between Serum IL-17, IL-35 Levels andClinicopathological Features and Prognosis in Patients with Prostate Cancer[J].Journal of Modern Laboratory Medicine,2021,36(05):96.[doi:10.3969/j.issn.1671-7414.2021.04.020]
[5]荣　蓉a,古　颖a,高　翔a,等.前列腺癌组织肝激酶B1，Rab鸟嘌呤核苷酸交换因子-5mRNA表达水平与临床病理特征和预后的相关性研究[J].现代检验医学杂志,2021,36(06):1.[doi:10.3969/j.issn.1671-7414.2021.06.001]
　RONG Rong,GU Ying,GAO Xiang,et al.Correlation between the Expression Levels of Liver Kinase B1, Rab Guanine Nucleotide Exchange Factor-5 mRNA in Prostate Cancer Tissues and Its Clinicopathological Characteristics and Prognosis[J].Journal of Modern Laboratory Medicine,2021,36(05):1.[doi:10.3969/j.issn.1671-7414.2021.06.001]
[6]张士保,朱斐煜,谢瑞玉,等.CircRNA-100395 基因通过启动子区甲基化调控miRNA-136-5p/Smad3 轴促进前列腺癌细胞增殖及侵袭的机制研究[J].现代检验医学杂志,2022,37(05):44.[doi:10.3969/j.issn.1671-7414.2022.05.010]
　ZHANG Shi-bao,ZHU Fei-yu,XIE Rui-yu,et al.Mechanism of CircRNA-100395 Promoter Methylation Promoting Prostate Cancer Cells Proliferation and Invasion by Regulating miRNA-136-5p/Smad3 Axis[J].Journal of Modern Laboratory Medicine,2022,37(05):44.[doi:10.3969/j.issn.1671-7414.2022.05.010]
[7]阴铭迪,李 林.前列腺癌实验室诊断的最新进展[J].现代检验医学杂志,2022,37(05):194.[doi:10.3969/j.issn.1671-7414.2022.05.039]
　YIN Ming-di,LI Lin.Recent Advances in Laboratory Diagnosis of Prostate Cancer[J].Journal of Modern Laboratory Medicine,2022,37(05):194.[doi:10.3969/j.issn.1671-7414.2022.05.039]
[8]郑江婷,寸淑娥,尹 冶,等.长链非编码RNA 在前列腺癌治疗抵抗中作用机制的研究进展[J].现代检验医学杂志,2023,38(01):199.[doi:10.3969/j.issn.1671-7414.2023.01.038]
　ZHENG Jiang-ting,CUN Shu-e,YIN Ye,et al.Research Progress of Long Non-coding RNA in the Therapeutic Resistance of Prostate Cancer[J].Journal of Modern Laboratory Medicine,2023,38(05):199.[doi:10.3969/j.issn.1671-7414.2023.01.038]
[9]孙 飞,黎春明.基于免疫细胞组织浸润的免疫评分模型预测前列腺癌免疫治疗效果及预后分析研究[J].现代检验医学杂志,2023,38(03):189.[doi:10.3969/j.issn.1671-7414.2023.03.035]
　SUN Fei,LI Chun-ming.Prediction of Immunotherapy Effect and Prognosis of Prostate Cancer Based on Immune Cell Tissue Infiltration Immune Score Model[J].Journal of Modern Laboratory Medicine,2023,38(05):189.[doi:10.3969/j.issn.1671-7414.2023.03.035]
[10]姚俊波,贾 波,刘加元,等.前列腺癌患者血清TWEAK 和SREBP-1 水平表达与临床病理特征及无进展生存预后的关系研究[J].现代检验医学杂志,2024,39(03):136.[doi:10.3969/j.issn.1671-7414.2024.05.023]
　YAO Junbo,JIA Bo,LIU Jiayuan,et al.Study on the Serum TWEAK and SREBP-1 Levels in Patients with Prostate Cancer and Their Relationship with Clinical Pathological Characteristics and Progression Free Survival Prognosis[J].Journal of Modern Laboratory Medicine,2024,39(05):136.[doi:10.3969/j.issn.1671-7414.2024.05.023]

备注/Memo

备注/Memo:
基金项目：河北省2023 年度医学科学研究课题计划（编号：20231915）。
作者简介：张珑（1979-），男，硕士研究生，副主任医师，研究方向：泌尿系肿瘤，E-mail：cpsbue@163.com。
更新日期/Last Update: 2024-09-15